RGC
Regencell Bioscience Holdings Ltd
NASDAQ: RGC · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$31.47
-9.79% today
Updated 2026-06-05
Market cap
$10.28B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.01
Dividend yield
—
52W range
$9 – $84
Volume
0.1M
WallStSmart proprietary scores
20
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.3
Quality
C+3.0
Profitability
D5.0
Valuation
C+2/9
Piotroski F-Score
Weak
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
—
—
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.32x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Thin margins at 0.00%
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | — | — |
| Net income | $-7.42M | $-5.87M | $-4.30M | $-3.58M | $-5.32M |
| EPS | — | — | — | — | $-0.01 |
| Free cash flow | $-6.05M | $-4.99M | $-4.01M | $-3.27M | — |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Regencell Bioscience Holdings Ltd trades at $31.47. Our Smart Value Score of 20/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score.
Frequently asked questions
What is Regencell Bioscience Holdings Ltd's stock price?
Regencell Bioscience Holdings Ltd (RGC) trades at $31.47.
Is Regencell Bioscience Holdings Ltd overvalued?
Regencell Bioscience Holdings Ltd carries a Smart Value Score of 20/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-806.06%
Beta1.64
50D MA$27.34
200D MA$22.29
Shares out0.49B
Float0.06B
Short ratio—
Avg volume0.1M
Performance
1 week-15.83%
1 month-26.86%
3 months-15.51%
YTD-4.81%
1 year—
3 years—
5 years—